TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy.

Journal: Journal Of The National Comprehensive Cancer Network : JNCCN
Published:
Relevant Conditions

Endometrial Cancer